According to Nova one advisor, the global Breast Biopsy Devices Market Size accounted for USD 2.96 billion in 2023 and is estimated to achieve a market size of USD 10.6 billion by 2032 growing at a CAGR of 7.9% from 2023 to 2032.
Key Insights:
- By product type, the image-guided biopsy segment is predicted to account for a sizeable portion.
- By guidance, the liquid biopsy segment is anticipated to grow the most from 2023 to 2032.
- By type, the fine-needle aspiration segment is predicted to have the highest share in 2023.
- North America contributed the largest revenue share in the worldwide market in 2023.
Changes in one's way of life, such as behaviour, nutritional preferences, and physical activity, might make breast cancer worse. Women who are overweight have higher blood insulin levels. Several cancers, particularly breast cancer, have been linked to elevated insulin levels.
Alcohol use, being overweight, using birth control, taking menopausal hormone therapy, and having breast implants are all lifestyle choices that can result in breast cancer. An increase in life expectancy is the reason that is anticipated to promote the expansion of the breast biopsy devices market.
Furthermore, a sophisticated biopsy strategy may enable radiologists and surgeons to perform breast procedures with greater accuracy, simplicity, and convenience. Large chances are being created for players to enter this industry and take over market space with new technology.
It will thus help the market to further grow, by improving the product offering in the market by the key players during the forecast period from 2023 to 2032.
Report Scope of the Breast Biopsy Devices Market
Segments Insight
Product Type Insights
Due to the rising popularity of image-guided procedures in both developed and developing countries as well as the development of cutting-edge and distinctive designs, the biopsy needles market is predicted to account for a sizeable portion of the breast biopsy market. Consider the tri-axial needle, which has a cutting needle on the exterior, a pincer needle on the outside, and a sharp style within. Healthcare professionals may cut through tissue without crushing it because of the needle's shape. Despite its unusual shape, the needle is clearly visible with CT and ultrasonography, which are frequently utilized for biopsy guidance.
Guidance Insights
The Guidance category with respect to liquid biopsy is anticipated to grow the most over the forecast period. A revolutionary technique that is broadening the range of cancer diagnostics is a liquid biopsy. The significant growth of the market may be attributed to the expanding use of cutting-edge NGS-based assays and droplet digital PCR technology for conducting liquid biopsies in the majority of developed nations. To bring new products to market, businesses in the sector are increasing their R&D spending. Thus, ongoing clinical trials and a prospective product pipeline will fuel additional market expansion.
Type Insights
This sector is divided into needle breast and open surgical biopsies according to kind. The first is further divided into vacuum-assisted core biopsy, core-needle aspiration, and both. Due mostly to an increase in demand for less invasive treatments, the fine-needle aspiration category is predicted to have the highest share in 2022. Contrarily, the less invasive vacuum-assisted core biopsy, which entails creating a tiny incision through which the needle is put, followed by sample collection using a vacuum-powered device, is predicted to expand at a high CAGR value throughout the projection period.
Regional Insights
North America accounted for the largest revenue share in the worldwide market in 2022, and it is anticipated that the region would continue to dominate the market during the forecast period. The U.S. and Canada, two of the region's biggest economies, are the main sources of income for the market value in the area. The prospective market for medical tourism in the area underpins the value of the prevailing regional market.
Furthermore, Asia Pacific is anticipated to grow at the fastest rate from 2023 to 2032, according to projections. The rapidly developing nations in the area have invested in the building of healthcare infrastructure, which is promoting the market growth. China, the world's second-largest economy, is expected to expand at a CAGR of 13.1% between 2023 and 2032, with a target market size of US$620.6 million. Other major geographic markets include Japan and Canada, which are expected to increase at rates of 4.8% and 7.8%, respectively, between 2023 and 2032. Germany is expected to expand within Europe at a rate of growth of around 5.8% CAGR. Additionally, as the diagnostic market in developing nations becomes more aware of breast biopsy procedures, businesses are able to invest in breast biopsy equipment in these developing markets. Rapid advancements in health technology in nations like China, India, and South Korea have prompted hospitals and other breast care facilities to make large expenditures in cutting-edge technologies (comprising liquid breast biopsy and vacuum-assisted biopsy devices, amongst others). For instance, Cytecare Hospital in Bengaluru, India, was acknowledged as the first hospital to offer 3D mammography (Digital Breast Tomosynthesis) to female patients. Since 3D Mammography creates many successive slides through the tissues using low concentrations of x-rays at various angles, it offers an advantage over 2D scans. The scans take 10 seconds, after which the computer receives the conclusions.
Some of the prominent players in the Breast Biopsy Devices Market include:
- Cook Medical Incorporated
- Becton, Dickinson and Company
- Devicor Medical Products Inc.
- C.R. Bard, Inc., Hologic Inc
- Argon Medical Devices
- Planmed OY
- Encapsule Medical Devices LLC
- Ethicon Endo-Surgery (Johnson and Johnson)
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Breast Biopsy Devices market.
By Product
- Biopsy Needles
- Guidance Systems
- Biopsy Tables
- Localization Wires
- Assay Kits
- Liquid Biopsy Instruments
- Others
By Guidance
- Image-Guided Biopsy
- Mammography-guided Stereotactic Biopsy
- Ultrasound-guided Biopsy
- MRI-guided Biopsy
- Other Guidance Techniques
- Liquid Biopsy
- NGS-based Biopsy
- PCR-based Biopsy
- Microarray-based Biopsy
By Type
- Needle Breast Biopsy
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy (FNAB)
- Vacuum-assisted Biopsy (VAB)
- Open Surgical Breast Biopsy
- Excisional
- Incisional
- Liquid Breast Biopsy
- Circulating Tumor Cells
- Circulating Tumor DNA (CtDNA)
- Other Biomarkers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Breast Biopsy Devices industry analysis from 2023 to 2032 to identify the prevailing Breast Biopsy Devices industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Breast Biopsy Devices industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Breast Biopsy Devices industry trends, key players, market segments, application areas, and market growth strategies.
Request Customization
Get a Sample
Get a Sample
Request Customization